{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T11:33:10Z","timestamp":1793100790709,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004857","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T00:00:00Z","timestamp":1323216000000}}],"reference-count":91,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004857.pub2","type":"journal-article","created":{"date-parts":[[2011,12,5]],"date-time":"2011-12-05T15:53:37Z","timestamp":1323100417000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Oxcarbazepine for acute affective episodes in bipolar disorder"],"prefix":"10.1002","volume":"2011","author":[{"given":"Akshya","family":"Vasudev","sequence":"first","affiliation":[{"name":"London Health Sciences Centre, Victoria Hospital; University of Western Ontario; 800 Commissioners Road East PO BOX 5010 London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Macritchie","sequence":"additional","affiliation":[{"name":"University of Edinburgh; Division of Psychiatry; Royal Edinburgh Hospital Edinburgh UK EH10 5HF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamini","family":"Vasudev","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre, Victoria Hospital; University of Western Ontario; 800 Commissioners Road East PO BOX 5010 London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Watson","sequence":"additional","affiliation":[{"name":"Royal Victoria Infirmary; Department of Psychiatry, Leazes Wing; Queen Victoria Rd Newcastle-upon-Tyne Tyne and Wear UK NE1 4LP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Geddes","sequence":"additional","affiliation":[{"name":"University of Oxford\/Warneford Hospital; Department of Psychiatry; Oxford UK OX3 7JX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan H","family":"Young","sequence":"additional","affiliation":[{"name":"Imperial College London; Division of Experimental Medicine, Centre for Mental Health; St Dunstan's Road London UK W6 8RP"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,7]]},"reference":[{"issue":"Suppl 1","key":"10.1002\/14651858.CD004857.pub2-BIB0001|cit1","first-page":"83","article-title":"Studies with oxcarbazepine in acute mania","volume":"5","author":"Emrich","year":"1990","journal-title":"International Clinical Psychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004857.pub2-BIB0002|cit2","first-page":"83","article-title":"Studies with oxcarbazepine (Trileptal) in acute mania","volume":"5","author":"Emrich","year":"1990","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pnpbp.2008.10.012","article-title":"Bipolar I and II disorder residual symptoms: Oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial","volume":"33(1)","author":"Juruena","year":"2009","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eurpsy.2008.12.014","article-title":"Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study","volume":"24(3)","author":"Kakkar","year":"2009","journal-title":"European Psychiatry: the Journal of the Association of European Psychiatrists"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0005|cit5","first-page":"139","article-title":"Carbamazepine and oxcarbazepine in the treatment of manic syndromes-studies in Germany","volume-title":"Anticonvulsants in affective disorders","author":"Mueller","year":"1984"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/00048670701261186","article-title":"Comparison of two anticonvulsants in a randomized, single-blind treatment of hypomanic symptoms in patients with bipolar disorder","volume":"41(5)","author":"Suppes","year":"2007","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1176\/ajp.2006.163.7.1179","article-title":"A double blind randomized placebo controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents","volume":"163","author":"Wagner","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1176\/ps.2008.59.10.1175","article-title":"Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence","volume":"59(10)","author":"Baldessarini","year":"2008","journal-title":"Psychiatric Services"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004857.pub2-BIB0009|cit9","first-page":"S39","article-title":"Efficacy and tolerability of oxcarbazepine in bipolar disorder: a prospective study on 24 patients [poster presentation]","volume":"11","author":"Benedetti","year":"2001","journal-title":"European Neuropsychopharmacology [6th ECNP Regional Meeting 19-21 May, Naples, Italy]"},{"issue":"1-3","key":"10.1002\/14651858.CD004857.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0165-0327(02)00407-X","article-title":"Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode","volume":"79","author":"Benedetti","year":"2004","journal-title":"Journal of Affective Disorders"},{"issue":"4","key":"10.1002\/14651858.CD004857.pub2-BIB0011|cit11","first-page":"245","article-title":"Combined prophylactic treatment of manic depressive illness with lithium and oxcarbazepine","volume":"58","author":"Cabrera","year":"1987","journal-title":"Nervenarzt"},{"issue":"5","key":"10.1002\/14651858.CD004857.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1034\/j.1399-5618.2003.00047.x","article-title":"Oxcarbazepine: clinical experience with hospitalized psychiatric patients","volume":"5","author":"Centorrino","year":"2003","journal-title":"Bipolar Disorders"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0013|cit13","unstructured":"Conway CR Nelson LA McGuire JM Bonan KE Abraham PF Baram VY Chibnall J An open-label study of adjunctive oxcarbazepine in the treatment of refractory bipolar disorder [abstract no: NR31] American Psychiatric Association Annual Meeting [New Research Abstracts] 2003 12"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/01.jcp.0000195911.13870.f3","article-title":"An open-label trial of adjunctive oxcarbazepine for bipolar disorder","volume":"26(1)","author":"Conway","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1089\/cap.2004.14.344","article-title":"Oxcarbazepine treatment of juvenile-onset bipolar disorder","volume":"14(3)","author":"Davanzo","year":"2004","journal-title":"Journal of Child & Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0016|cit16","unstructured":"Deutschman DA Deutschman DH Chalekian JS Oxcarbazepine efficacy and safety in bipolar disorder: review of 249 patients [abstract no: NR246] American Psychiatric Association Annual Meeting [New Research Abstracts] 2003 92"},{"issue":"2","key":"10.1002\/14651858.CD004857.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0091-3057(83)90067-9","article-title":"Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report","volume":"19","author":"Emrich","year":"1983","journal-title":"Pharmacology, Biochemistry and Behavior"},{"issue":"3","key":"10.1002\/14651858.CD004857.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0165-0327(85)90022-9","article-title":"The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders","volume":"8","author":"Emrich","year":"1985","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1034\/j.1399-5618.2002.40104.x","article-title":"Oxcarbazepine treatment of refractory bipolar disorder: a retrospective chart review","volume":"4","author":"Ghaemi","year":"2002","journal-title":"Bipolar Disorders"},{"issue":"8","key":"10.1002\/14651858.CD004857.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"943","DOI":"10.4088\/JCP.v64n0813","article-title":"Oxcarbazepine treatment of bipolar disorder","volume":"64","author":"Ghaemi","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0021|cit21","first-page":"491","article-title":"Prophylactic treatment of affective disorders with carbamazepine and oxcarbazepine: an open clinical trial","volume-title":"Psychiatry: The state of the art [proceedings of VII World Congress of Psychiatry, 11-16 July 1983, Vienna, Austria]","author":"Greil","year":"1985"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1034\/j.1399-5618.2002.02228.x","article-title":"Acute antimanic efficacy and safety of carbamazepine in an open trial with an on-off-on design","volume":"4","author":"Hummel","year":"2002","journal-title":"Bipolar Disorders"},{"issue":"1-2","key":"10.1002\/14651858.CD004857.pub2-BIB0023|cit23","first-page":"90","article-title":"Oxcarbazepine in a carbamazepine-intolerant patient with bipolar affective disorder: a case report","volume":"18","author":"Kalra","year":"2006","journal-title":"Psychiatria Danubina"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004857.pub2-BIB0024|cit24","first-page":"S4","article-title":"Clinico-pharmacokinetic prognosis of prophylactic efficacy of carbamazepine, oxcarbazepine and sodium valproate in affective and schizoaffective disorders [conference poster p1.081]","volume":"6","author":"Kouzavkova","year":"1996","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0025|cit25","unstructured":"Lattanzi L Benedetti A Pini S Ceraudo G Musetti L Cassano B Oxcarbazepine as add on treatment in patients with bipolar manic, mixed or depressive episode Fifth international conference of bipolar disorder 2003"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00131746-200607000-00003","article-title":"A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder","volume":"12(4)","author":"MacMillan","year":"2006","journal-title":"Journal of Psychiatric Practice"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/SMJ.0b013e31802fa124","article-title":"Oxcarbazepine treatment of refractory bipolar illness","volume":"100(4)","author":"Majczenko","year":"2007","journal-title":"Southern Medical Journal"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.eurpsy.2008.05.003","article-title":"Efficiency and safety of oxcarbazepine in mood disorders: a naturalistic study exploring the interest of plasma dosages","volume":"23(6)","author":"Misdrahi","year":"2008","journal-title":"European Psychiatry: the Journal of the Association of European Psychiatrists"},{"issue":"10","key":"10.1002\/14651858.CD004857.pub2-BIB0029|cit29","first-page":"36","article-title":"Comparative efficacy and tolerability of carbamazepine and oxcarbazepine during long therapy of patients with bipolar and schizoaffective disorders [Russian]","volume":"109","author":"Mosolov","year":"2009","journal-title":"Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0030|cit30","unstructured":"Mueller AA Stoll KD Wendt G Oxcarbazepine in acute mania Proceedings of the VII World Congress of Psychiatry; 1983 July 11-16; Vienna, Austria 1983 124"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0031|cit31","unstructured":"Mueller AA Stoll KD Kraemer G Goncalves N Carbamazepine, Oxcarbazepine and their metabolites. Studies in healthy volunteers, cases with epilepsy and patients with manic syndromes [abstract] Collegium Internationale Neuro-Psychopharmacologicum:14th CINP Congress; June 19-23, 1984; Florence, Italy 1984 1073"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0032|cit32","unstructured":"Munoz RA Oxcarbazepine for the treatment of bipolar disorder [poster presentation, no: NR479] American Psychiatric Association Annual Meeting [New Research Abstracts] 2002 129"},{"issue":"10","key":"10.1002\/14651858.CD004857.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1176\/appi.ajp.159.10.1793","article-title":"Oxcarbazepine for mood disorders","volume":"159","author":"Nasr","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0034|cit34","unstructured":"Nasr SJ Casper M Oxcarbazepine in the treatment of mood disorders American Psychiatric Association Meeting 2003"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0035|cit35","unstructured":"Boehm G Burkhart G Hershkowitz N Katz RG Fisher A Fitzgerald GG et al [FDA Centre for Drug Evaluation and Research (CEDR)] Trileptal Medical Review Part 7 [NDA 21-014, mania trial] Drugs@FDA [http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/21-014_Trileptal.cfm] 1999 (accessed 31 October 2011)"},{"issue":"12","key":"10.1002\/14651858.CD004857.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/001857870103601207","article-title":"Oxcarbazepine in mood disorders","volume":"36","author":"Norton","year":"2001","journal-title":"Hospital Pharmacy"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0037|cit37","unstructured":"Platt DE Munasifi FA McKay LM Retrospective chart review on the use of oxcarbazepine in patients with bipolar disorder [poster presentation, no: NR519 ] American Psychiatric Association Annual Meeting [New Research Abstracts] 2003 194"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004857.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1399-5618.2005.00253.x","article-title":"Oxcarbazepine add-on in the treatment of refractory bipolar disorder","volume":"7","author":"Pratoomsri","year":"2005\u00a0","journal-title":"Bipolar Disorders"},{"issue":"4","key":"10.1002\/14651858.CD004857.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1017\/S1461145703003754","article-title":"Oxcarbazepine vs. valproate in the treatment of mood and schizoaffective disorders","volume":"6","author":"Raja","year":"2003","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD004857.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2165\/00044011-200323100-00006","article-title":"Oxcarbazepine versus divalproex sodium for the continuing treatment of mania","volume":"23","author":"Reinstein","year":"2003","journal-title":"Clinical Drug Investigation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004857.pub2-BIB0041|cit41","first-page":"S75","article-title":"Impulsivity in bipolar disorder: a randomized clinical trial of adjunctive oxcarbazepine [poster presentation, p.3.16]","volume":"19","author":"Rosa","year":"2009","journal-title":"European Neuropsychopharmacology [papers of the 2009 ECNP Workshop on Neuropsychopharmacology for Young Scientists in Europe; Nice, France]"},{"issue":"2","key":"10.1002\/14651858.CD004857.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.yebeh.2006.06.004","article-title":"Clinical experience with anticonvulsant medication in pediatric epilepsy and comorbid bipolar spectrum disorder","volume":"9","author":"Salpekar","year":"2006","journal-title":"Epilepsy and Behavior"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0043|cit43","unstructured":"Schaffer CB Schaffer LC Oxcarbazepine for refractory bipolar disorder Fifth international conference on bipolar disorder 2003"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004857.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"s339","DOI":"10.1016\/S0924-9338(00)94477-8","article-title":"Oxcarbazepine as a mood regulator: its efficacy, safety and tolerability versus carbamazepine [poster presentation, no: p01.70]","volume":"15","author":"Tavormina","year":"2000","journal-title":"European Psychiatry [abstracts of the Congress of the Association of European Psychiatrists; Prague, Czech Republic]"},{"issue":"9","key":"10.1002\/14651858.CD004857.pub2-BIB0045|cit45","first-page":"993","article-title":"Oxcarbazepine in bipolar disorder","volume":"40","author":"Teitelbaum","year":"2001","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0046|cit46","first-page":"208","article-title":"Effect of oxcarbazepine on affective and schizoaffective symptoms: A Preliminary Report","volume-title":"Anticonvulsants in affective disorders (International Congress Series; no 626)","author":"Velikonja","year":"1984"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0047|cit47","first-page":"445","article-title":"A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder","volume":"11(4)","author":"Vieta","year":"2008","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004857.pub2-BIB0048|cit48","first-page":"89","article-title":"Case studies on prophylactic long term effects of oxcarbazepine in recurrent affective disorders","volume":"5","author":"Wildgrube","year":"1990","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0049|cit49","unstructured":"Talaei A Soltanifar A Therapeutic Efficacy of Oxcarbazepine and Sodium Valproate in Acute Mania [IRCT201012055280N2] Iranian Clinical Trials Registry [http:\/\/www.irct.ir\/index.php] 2011"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1002\/sim.2423","article-title":"Meta-analysis of heterogeneously reported trials assessing change from baseline","volume":"24","author":"Abrams","year":"2005","journal-title":"Statistics in Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004857.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0165-0327(00)00203-2","article-title":"Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders","volume":"59","author":"Akiskal","year":"2000","journal-title":"Journal of Affective Disorders"},{"issue":"7066","key":"10.1002\/14651858.CD004857.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0053|cit53","volume-title":"Diagnostic and Statistics Manual of mental disorders (DSM-IV)-TR (Text Revision)","author":"American Psychiatric Association","year":"2000"},{"issue":"4","key":"10.1002\/14651858.CD004857.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1600-0447.1979.tb04484.x","article-title":"The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale","volume":"59","author":"Bech","year":"1979","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD004857.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1517\/14656566.3.1.59","article-title":"Oxcarbazepine","volume":"3","author":"Beydoun","year":"2002","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD004857.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00004714-199604001-00006","article-title":"Role of newer medications for bipolar disorder","volume":"16","author":"Bowden","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD004857.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1089\/cap.2004.14.344","article-title":"Oxcarbazepine treatment of juvenile-onset bipolar disorder","volume":"14","author":"Davanzo","year":"2004","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD004857.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1055\/s-2001-18036","article-title":"Oxcarbazepine in affective and schizoaffective disorders","volume":"34","author":"Dietrich","year":"2001","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/01.wnl.0000188819.45330.90","article-title":"Hyponatremia from oxcarbazepine and carbamazepine","volume":"65","author":"Dong","year":"2005","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD004857.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1177\/0269881107085238","article-title":"Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study","volume":"22","author":"Franks","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD004857.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ije\/31.1.72","article-title":"Can we individualize the 'number needed to treat\u2019? An empirical study of summary effect measures in meta-analyses","volume":"31","author":"Furukawa","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0063|cit63","volume-title":"New Oxford Textbook of Psychiatry","author":"Gelder","year":"2003"},{"issue":"2","key":"10.1002\/14651858.CD004857.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1192\/bjp.164.2.149","article-title":"Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder","volume":"164","author":"Goodwin","year":"1994","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD004857.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/0269881109102919","article-title":"Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology","volume":"23","author":"Goodwin","year":"2009","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0066|cit66","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"56\u201362","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0165-0327(02)00338-5","article-title":"Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability","volume":"72 Suppl 1","author":"Hellewell","year":"2002","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org 2008","DOI":"10.1002\/9780470712184"},{"issue":"6","key":"10.1002\/14651858.CD004857.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1528-1157.1994.tb01792.x","article-title":"Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine","volume":"35","author":"Isojarvi","year":"1994","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004857.pub2-BIB0071|cit71","first-page":"33","article-title":"Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia","volume":"61","author":"Keck","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0072|cit72","article-title":"The Child Heath Questionnaire(CHQ) : A user's manual","volume-title":"The Child Heath Questionnaire(CHQ) : A user's manual","author":"Landgraf","year":"1999"},{"issue":"1","key":"10.1002\/14651858.CD004857.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004052","article-title":"Valproate for acute mood episodes in bipolar disorder","author":"Macritchie","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD004857.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1517\/14656566.8.5.649","article-title":"Oxcarbazepine in bipolar disorder: a critical review of the literature","volume":"8","author":"Mazza","year":"2007","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1192\/bjp.171.2.113","article-title":"Lithium: evidence reconsidered","volume":"171","author":"Moncrieff","year":"1997","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"382\u20139","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0077|cit77","first-page":"139","article-title":"Carbamazepine and oxcarbazepine in the treatment of manic syndromes: studies in Germany","volume-title":"Anticonvulsants in affective disorders","author":"Muller","year":"1984"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0079|cit79","article-title":"Preparing and maintaining systematic reviews","volume-title":"Cochrane Collaboration Handbook","volume":"section VI, upd","author":"Oxman","year":"1995"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0080|cit80","volume-title":"Physicians' Desk Reference","author":"Medical Economics Co","year":"2001"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00004583-198403000-00011","article-title":"Preliminary studies of the reliability and validity of the children's depression rating scale","volume":"23","author":"Poznaski","year":"1984","journal-title":"Journal of the American Academy of Child Psychiatry"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0082|cit82","volume-title":"The American Psychiatric Publishing Textbook of Psychopharmacology","author":"Schatzberg","year":"2004"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","article-title":"Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP","volume":"73","author":"Spearing","year":"1997","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0084|cit84","volume-title":"Essential psychopharmacology of depression and bipolar disorder","author":"Stahl","year":"2000"},{"issue":"12","key":"10.1002\/14651858.CD004857.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/archpsyc.1991.01810360046007","article-title":"Risk of recurrence following discontinuation of lithium treatment in bipolar disorder","volume":"48","author":"Suppes","year":"1991","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD004857.pub2-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004694.pub2","article-title":"Tiagabine in the treatment of acute affective episodes in bipolar disorder","author":"Vasudev","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD004857.pub2-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003384.pub2","article-title":"Topiramate for acute affective episodes in bipolar disorder","author":"Vasudev","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00023210-200620030-00004","article-title":"Extended-release carbamazepine capsules as monotherapy in bipolar disorder - Pooled results from two randomised, double-blind, placebo-controlled trials","volume":"20","author":"Weisler","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0089|cit89","volume-title":"The ICD-10 Classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines","author":"World Health Organisation","year":"1992"},{"key":"10.1002\/14651858.CD004857.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD004857.pub2-BIB0091|cit91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004694.pub2","article-title":"Tiagabine in the treatment of acute affective episodes in bipolar disorder: efficacy and acceptability","author":"Young","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004857.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:47:39Z","timestamp":1793098059000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004857.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,12,7]]},"references-count":91,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004857.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,7]]}}}